Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Stuart Hill

Mr Stuart Hill, MRPharmS

Recent stories

  • Theory alone is obviously surpassed by clinical evidenceSubscription

    PJ, 21/28 June 2014, Vol 292, No 7815/6

    I would like to make clear that I take no issue with the proactive identification of potential safety concerns, as suggested by the UKCPA group. The opening sentence in my letter should have made that clear

  • Do not dismiss Relvar Ellipta based on theoretical concernsSubscription

    PJ, 10/17 May 2014, Vol 292, No 7809/10

    Although the promotion of medicines safety should be applauded, I disagree with the concerns of Tony Capstick and colleagues (PJ, 22 February 2014, p199) because they do not appear to be evidence based. Although comparative potencies of corticosteroids is an important issue, this lies in the theoretical realm. If randomised controlled trials assessing patient-oriented outcomes have shown the product to fall into the category of

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.